Sunvozertinib significantly improved progression-free survival and response rates versus platinum-doublet chemotherapy in the Phase 3 WU-KONG28 trial, positioning the EGFR inhibitor as a potential first-line standard of care for patients with EGFR exon20 insertion-mutated NSCLC.
Written By: Nikita Jha, BPharm
Fact-Checked By: Chikkula Pavan Kumar, PharmD
Reviewed By: Pharmacally Editorial Team
Dizal reported positive results from the global Phase 3 WU-KONG28 study (NCT05668988) showing that ZEGFROVY (sunvozertinib) significantly improved outcomes compared with platinum-doublet chemotherapy in previously untreated advanced non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion (exon20ins) mutations.
The findings were presented as a Late-Breaking Oral Abstract at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The New England Journal of Medicine.
Addressing a Long-Standing Treatment Gap
EGFR exon20ins mutations represent a distinct subset of EGFR-driven NSCLC that has remained difficult to treat with earlier-generation EGFR inhibitors. As a result, platinum-based chemotherapy has continued as the frontline standard despite limited durability.
Sunvozertinib is an irreversible EGFR inhibitor that selectively targets EGFR mutations while sparing wild-type EGFR and is already approved in the United States and China for previously treated EGFR exon20ins NSCLC.
WU-KONG28 Demonstrates Superior Efficacy
The multinational, open-label, randomized Phase 3 trial enrolled 324 patients across 15 countries and regions. Participants received either oral sunvozertinib 300 mg once daily or platinum-doublet chemotherapy.
At the January 16, 2026 data cutoff, sunvozertinib reduced the risk of disease progression or death by 35% compared with chemotherapy (HR 0.65; p=0.0008). Median progression-free survival reached 10.3 months versus 7.5 months.
The efficacy benefit extended across secondary endpoints. Objective response rate was 68.1% with sunvozertinib compared with 35.4% for chemotherapy, while median duration of response reached 11.2 months versus 7.1 months. The response rate nearly doubled versus chemotherapy, reinforcing the consistency of benefit across efficacy measures.
The safety profile remained consistent with previous studies, with no new safety signals identified.
Investigators Highlight Paradigm Shift
Presenting author Dr. John Heymach of MD Anderson Cancer Center said the findings demonstrate that a single-agent targeted therapy can deliver superior antitumor activity compared with conventional chemotherapy and may allow patients to avoid initial cytotoxic treatment.
Lead investigator Dr. Caicun Zhou added that the combination of efficacy, manageable safety, and oral administration supports a chemotherapy-free treatment approach for patients with EGFR exon20ins NSCLC.
Regulatory Path Forward
China’s National Medical Products Administration (NMPA) has accepted a New Drug Application seeking approval of sunvozertinib as a first-line treatment for EGFR exon20ins NSCLC and granted Priority Review status.
The WU-KONG28 study is the first positive global Phase 3 trial to show superior efficacy for a targeted therapy over platinum-based chemotherapy in the frontline EGFR exon20ins setting. If approved globally, sunvozertinib could become the first targeted therapy to establish a chemotherapy-free first-line standard of care for this patient population.
Reference
About the Writer
Nikita Jha, BPharm (LinkedIn) a pharmacy graduate specializing in medical writing, with a strong ability to interpret complex medical and regulatory information and translate it into clear, accurate, and evidence-based healthcare content. Known for her attention to detail and precision, she focuses on delivering high-quality scientific communication that supports drug safety and informed decision-making.